Role of COX-2/mPGES-1/prostaglandin E2 cascade in kidney injury

Zhanjun Jia1, Yue Zhang1, Guixia Ding1

  • 1Nanjing Key Laboratory of Pediatrics, Nanjing Children's Hospital Affiliated to Nanjing Medical University, Nanjing 210008, China ; Department of Nephrology, Nanjing Children's Hospital Affiliated to Nanjing Medical University, Nanjing 210008, China.

Insights

The cyclooxygenase-2/microsomal prostaglandin E synthase-1/prostaglandin E2 (COX-2/mPGES-1/PGE2) cascade is vital in kidney function and disease. This review explores its role in various kidney injuries, offering new therapeutic strategies.

Area of Science:

  • Nephrology
  • Molecular Biology
  • Pathophysiology

Background:

  • The cyclooxygenase-2/microsomal prostaglandin E synthase-1/prostaglandin E2 (COX-2/mPGES-1/PGE2) cascade is crucial for physiological and pathological processes in organs.
  • In the kidney, this pathway regulates fluid balance, blood pressure, and renal hemodynamics.
  • Dysregulation of this cascade is implicated in various kidney disease conditions.

Purpose of the Study:

  • To review the roles of the COX-2/mPGES-1/PGE2 cascade in the pathogenesis of kidney injuries.
  • To discuss its involvement in diabetic kidney disease, non-diabetic kidney diseases, and acute kidney injuries.
  • To provide new insights into the pathological mechanisms and potential therapeutic targets.

Main Methods:

  • Literature review of existing studies on the COX-2/mPGES-1/PGE2 pathway in kidney injury.
  • Synthesis of information regarding the cascade's function in different renal disease models.
  • Analysis of current understanding of the pathway's involvement in kidney pathogenesis.

Main Results:

  • The COX-2/mPGES-1/PGE2 cascade significantly contributes to the development and progression of various kidney injuries.
  • Specific roles and actions of the cascade differ based on the type of pathological insult.
  • Understanding these roles is key to deciphering disease mechanisms.

Conclusions:

  • The COX-2/mPGES-1/PGE2 pathway is a critical factor in kidney injury pathogenesis.
  • New insights enhance comprehension of the pathway's pathological significance.
  • This knowledge can drive the development of innovative treatment strategies for kidney diseases.

Related Concept Videos

Acute Kidney Injury II: Pathophysiology01:29

Acute Kidney Injury II: Pathophysiology

Acute kidney injury (AKI) causes are categorized into three primary categories based on the location of the injury: prerenal, intrarenal (or intrinsic), and postrenal causes. This classification guides clinical management and illustrates how different pathways can impair kidney function.Etiology and Pathophysiology of Acute Kidney Injury1. Prerenal causesEtiology: Prerenal Acute Kidney Injury, the most common type, occurs when reduced blood flow to the kidneys decreases filtration capacity...
2.1K
Acute Kidney Injury I: Introduction01:22

Acute Kidney Injury I: Introduction

Introduction:Acute Kidney Injury (AKI) describes a swift decrease in kidney function occurring over hours to days, characterized by the kidneys' failure to remove waste products from the bloodstream. This leads to dangerous complications like metabolic acidosis, fluid overload, and electrolyte imbalances, such as hyperkalemia, which can cause life-threatening arrhythmias. AKI is common in both hospital and outpatient settings, often triggered by dehydration, sepsis, or exposure to nephrotoxic...
1.3K
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
1.7K
Gastritis-II: Pathophysiology01:17

Gastritis-II: Pathophysiology

Gastritis is marked by disruption of the mucosal barrier that usually protects the stomach tissue from digestive juices and manifests in acute and chronic forms.
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
1.8K
Acute Kidney Injury III: Clinical Manifestations01:29

Acute Kidney Injury III: Clinical Manifestations

Acute Kidney Injury (AKI) progresses through distinct clinical phases: the oliguric, diuretic, and recovery phases, each marked by unique manifestations and challenges.Oliguric Phase:The oliguric phase is the initial stage of AKI, typically lasting 10 to 14 days. This phase is marked by a significant reduction in urine output, usually less than 400 mL per day, indicating decreased kidney function. Fluid retention is a prominent feature, leading to symptoms such as edema, hypertension, and...
1.6K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.6K